Intech Investment Management LLC Acquires 6,803 Shares of Kymera Therapeutics, Inc. $KYMR

Intech Investment Management LLC raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 46.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,514 shares of the company’s stock after acquiring an additional 6,803 shares during the quarter. Intech Investment Management LLC’s holdings in Kymera Therapeutics were worth $1,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Larson Financial Group LLC lifted its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Raymond James Financial Inc. bought a new position in shares of Kymera Therapeutics in the second quarter worth $73,000. Finally, US Bancorp DE raised its position in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after buying an additional 166 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective on the stock. Citigroup raised their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Stephens lifted their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Finally, UBS Group boosted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $118.10.

Insider Buying and Selling at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $54,081,710.10. The trade was a 4.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director directly owned 5,641 shares of the company’s stock, valued at $507,464.36. This trade represents a 51.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 260,115 shares of company stock valued at $21,218,138. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Up 1.9%

Shares of KYMR opened at $74.61 on Friday. The stock has a market capitalization of $6.14 billion, a P/E ratio of -20.90 and a beta of 2.02. The firm has a fifty day simple moving average of $83.11 and a two-hundred day simple moving average of $79.73. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.82) EPS. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.3 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.